Last reviewed · How we verify

Idiopathic Pulmonary Fibrosis (IPF) — Treatment Landscape & Competitive Intelligence

Idiopathic Pulmonary Fibrosis (IPF) (Respiratory) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Respiratory 4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Idiopathic Pulmonary Fibrosis (IPF), deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Jascayd NERANDOMILAST Boehringer Ingelheim 2025-01-01
Ofev NINTEDANIB Boehringer Ingelheim Kinase Inhibitor Receptor-type tyrosine-protein kinase FLT3 2014-01-01
OFEV® OFEV® Boehringer Ingelheim Kinase Inhibitor Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2
vargatef vargatef ARCAGY/ GINECO GROUP Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Boehringer Ingelheim · 3 drugs in Idiopathic Pulmonary Fibrosis (IPF)
  2. ARCAGY/ GINECO GROUP · 1 drug in Idiopathic Pulmonary Fibrosis (IPF)

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Idiopathic Pulmonary Fibrosis (IPF):

Cite this brief

Drug Landscape (2026). Idiopathic Pulmonary Fibrosis (IPF) — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/idiopathic-pulmonary-fibrosis. Accessed 2026-05-16.

Related